modelDesmopressin_1
Extends from Pharmacolibrary.Drugs.ATC.H.H01BA02_1.
Information
| name: | Desmopressin_1 | |
| ATC code: | H01BA02_1 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 0.002 | mg |
| volume of distribution: | 33.7 | L |
| clearance: | 7.6 | L/h |
| other parameters in model implementation | ||
Desmopressin is a synthetic analogue of the natural pituitary hormone vasopressin. It is primarily used in the treatment of diabetes insipidus, nocturnal enuresis, and certain bleeding disorders such as hemophilia A and von Willebrand's disease. The drug is approved and widely used today.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult males after intravenous administration.
References
de Jager, NCB, et al., & Mathôt, RAA (2020). Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. Thrombosis and haemostasis 120(10) 1407–1416. DOI:10.1055/s-0040-1714349 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32746466
Heijdra, JM, et al., & Mathôt, RAA (2022). Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study. Haemophilia : the official journal of the World Federation of Hemophilia 28(5) 814–821. DOI:10.1111/hae.14582 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35526239
Schütte, LM, et al., & Mathôt, RAA (2018). Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients. Thrombosis and haemostasis 118(4) 621–629. DOI:10.1160/TH17-06-0390 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29458233
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)